DIGITAL HEALTH LEARNING NETWORK
The Digital Health Learning Network (DHLN) is a group of innovation leaders from industry, who come together specifically to understand what a patient-centric future means for Life Sciences and Healthcare. The DHLN is hosted and supported by Cambridge Digital Innovation, organising the Network’s meetings, facilitating networking, and developing knowledge through white papers, podcasts, and webinars.
As the industry moves towards a patient-centric future the key questions of how this will manifest, what will enable it, the regulatory effect, and most importantly how this will help people lead healthy lives, must be addressed. Digital innovation is accelerating the pace of these changes, so it has never been more important, or challenging, for leaders in Life Science and Healthcare to understand the nature of impending disruptive innovations.
Objectives
Help companies operating in Life Science & Healthcare identify disruptive innovations.
Build a community of like-minded people in digital transformation.
Encourage innovators to develop offerings with customers and collaborators.
Develop a medium- to long-term perspective on how Life Science & Healthcare could develop.
Areas of interest
Internet of things
Devices capable of interconnecting to collect and exchange data.
Cognitive computing
Self-learning systems that use data mining, pattern recognition and natural language processing.
Social Engagement
Degree of participation in a community or society.
Members
Meetings
07 Dec 2017
06 Sep 2017
29 Mar 2017
The Digital Health Learning Network (DHLN) is a group of innovation leaders from industry, who come together specifically to understand what a patient-centric future means for Life Sciences and Healthcare. The DHLN is hosted and supported by Cambridge Digital Innovation, organising the Network’s meetings, facilitating networking, and developing knowledge through white papers, podcasts, and webinars.
As the industry moves towards a patient-centric future the key questions of how this will manifest, what will enable it, the regulatory effect, and most importantly how this will help people lead healthy lives, must be addressed. Digital innovation is accelerating the pace of these changes, so it has never been more important, or challenging, for leaders in Life Science and Healthcare to understand the nature of impending disruptive innovations.
Objectives
Help companies operating in Life Science & Healthcare identify disruptive innovations.
Build a community of like-minded people in digital transformation.
Encourage innovators to develop offerings with customers and collaborators.
Develop a medium- to long-term perspective on how Life Science & Healthcare could develop.
Meetings
Next meeting
TBA
Previous meetings
18 Jun 2018
Health data security, the future of tele-health & innovation scaling
15 Mar 2018
Developing innovation in the health ecosystem
7 Dec 2017
Nurturing innovation
7 Sep 2017
New approaches to patient engagement
30 Mar 2017
Impact of artificial intelligence
Areas of interest
Internet of things
Devices capable of interconnecting to collect and exchange data.
Cognitive computing
Self-learning systems that use data mining, pattern recognition and natural language processing.
Social Engagement
Degree of participation in a community or society.
Outputs
The outputs of DHLN meetings are available online.
Selected DHLN Briefs include:
Microservices: Designing for innovation
Design thinking for nurturing innovation
Click here to access further outputs from all the DHLN meetings.
Members
Junaid Bajwa
Executive Director of Healthcare Services, MSD
Prof Michael Barrett
Cambridge Judge Business School
Christina Donatti
IMI Lead, Real World Evidence, EMEA Strategic Organisation, Janssen Cilag
Dr Amer Fasihi
Founder, Caros Connect
Shahid Hanif
Head of Health Data & Outcomes, Association of the British Pharmaceutical Industry
Sammeli Liikkanen
Chief Digital Officer, Orion Corporation
Guido Radack
Director, Global Clinical Information Technology & Solutions, Bayer HealthCare
Pratik Thakkar
Medical Advisor (Immuno-oncology), Bristol-Myers Squibb